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ABSTRACT
Metabolic syndrome (MetS) is a common and complex disorder combininghypertension, obesity, dyslipidemia,
and insulin resistance. MetS represents a risk factor for changes in cognitive functions in older age, and several
studies have suggested thatMetSmay be linked to dementia. This article reviews themain evidences about the
relationship betweenMetS and neurodegenerative disease. Starting from an epidemiological point of view, the
article analyzes medico-social aspects related to MetS, considering the reduction of work capacity and the
condition of disability that it involves. Some authors affirm that on the basis of current Italian legislation, it is
possible to consider the syndromeas adisability. This is because all thediseases thatmake upMetS are high-risk
clinical pathological conditions. For these reasons, a joint action is required to contain the incidenceofMetS, the
high social costs, and the loss of productivity related to the syndrome. In conclusion, healthcare initiatives could
be adopted in order to increase the understanding of the pathogenic contributions of each element on MetS
and how they can be modified. These actions will be useful to reduce healthcare costs and can lead to more
effective prevention of metabolic disease, thus promoting good health.
Abbreviations: MetS: Metabolic syndrome; WHO: World Health Organization; CVD: cerebrovascular
diseases; AD: Alzheimer’s Disease; VaD: Vascular Dementia; IDF: International Diabetes Federation;
T2DM: type 2 diabetes mellitus; CAD: coronary artery disease; MCI: mild cognitive impairment; NCDs:
Non Communicable Diseases; BMI: Body Mass Index; ICIDH: International classification of impairments,
disabilities and handicaps
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Introduction
Metabolic syndrome (MetS) is a common and complex disorder
combining obesity, dyslipidemia, insulin resistance, and hyper-
tension. It represents a dangerous risk factor for cardiovascular
disease and diabetes. The concept of MetS, also known as insulin
resistance syndrome, was introduced in 1988 (1). Since then,
various definitions of MetS have been proposed from the World
Health Organization (WHO) (2), the European Group for Study
of Insulin Resistance (EGIR) (3), the National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATP
III) (4) and the International Diabetes Federation (IDF) (5).
The pathogenesis ofMetS remains little known and the difficulty
of the study of this condition is compounded by the heteroge-
neity of the different phenotypes, determined by different com-
binations of risk factors.
Several investigations have suggested that MetS may be
linked to the risk of developing cognitive decline and
Vascular Dementia (VaD) (6). Recently, a systematic review
and meta-analysis of 19,522 subjects aged 59–85 years from 13
longitudinal population-based studies was conducted to
examine the association between MetS and longitudinal
changes in cognitive functions (7).
MetS is also a medicolegal and especially a medico-social
problem, if we consider the reduction of work capacity and the
condition of disability that it involves. In industrialized countries,
cardio-cerebrovascular diseases (CVDs) are the leading cause of
morbidity and disability. MetS also has a socioeconomic impact if
we consider that costs will rise as the elderly population increases.
According to Alzheimer’s Disease International (ADI), the
cost of dementia including informal care provided by family
and others, social care provided by community care profes-
sionals, and the direct costs of medical care are daunting for
the growing numbers of people involved (8). This situation
will require an increase in long-term care for elderly people
with MetS-related cerebrovascular disease.
In the European Union countries, particularly in Italy, this
situation has triggered various initiatives and projects aimed at
informing and educating the population toward healthier life-
styles (9). It has been shown that simply by acting on prevention
it will be possible to contain the social costs of MetS and diseases
related to it. It is important to note that attention is on research
and prevention to improve the quality of life as well as reduce the
social costs of the disease.
Metabolic syndrome definition
In 1999, WHO defined MetS as glucose intolerance,
impaired glucose tolerance (IGT) or type-2 diabetes
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mellitus (T2DM), and/or insulin resistance, together with
two or more of the following components: raised arterial
pressure, raised plasma triglyceride, central obesity, micro-
albuminuria (2).
In due course of time, various authors contributed to identify
MetS, with the aim of reaching a common and shared definition,
modifying risk factors, and reference values. The European
Group for Study of Insulin Resistance (EGIR) proposed a mod-
ification of theWHOdefinition, using the term insulin resistance
syndrome rather than MetS introducing the waist circumference
(WC) for evaluation of abdominal obesity and elevated plasma
insulin (Tables 1) (3).
After this, the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) proposed to
define MetS in a subject exhibiting three or more of the
following criteria: abdominal obesity, hypertrigliceridemia,
low HDL-C, high blood pressure (BP), high fasting glucose
(10). The American Association of Clinical Endocrinologists
(AACE) considered as major criteria IGT, elevated triglycer-
ides, reduced HDL-C, elevated BP, and obesity (Table 1) (11).
A last definition of MetS was proposed by the International
Diabetes Federation (IDF). Those involved in establishing the
definition agreed that diabetes and insensitivity to insulin had
been overemphasized in the earlier definitions, and that the
‘essential’ component is central obesity – measured by waist
circumference (WC). Ethnicity-specific cut-off points have
been selected based on available data linkingwaist circumference
to other components of the MetS in different populations (12).
The IDF definition takes into account the mounting evidence
that central adiposity is common to each of the components of
MetS (Tables 1). An increased waist circumference, an accepted
proxy measurement for abdominal adiposity, is now a necessary
requirement for a diagnosis of the syndrome. Thus, the initial
screening test for MetS, by simply measuring the waist with a
tape measure, can be carried out easily and cheaply – anywhere
in the world. Research has shown that between population
groups, there are varying levels of central obesity at which the
risk of other illnesses begins to rise. Therefore, ethnicity-specific
waist circumference cut-off points have been incorporated in the
IDF global definition. For example, for people of south and
Southeast Asian origin, 90 cm and 80 cm are the cut-off points
for men and women, respectively (5,13,14). In 2005, the
American Heart Association (AHA), and the National Heart,
Lung, and Blood Institute (NHLBI), different from IDF, main-
tained the ATP III criteria except for minor modifications
(Table 1). This decision was based on the conclusion that ATP
III criteria are simple to use in a clinical setting and have the
advantage of avoiding emphasis on a single cause (15).
Finally, a simplified definition of MetS was given by a
research group that has proposed that WC be replaced by
Index of Central Obesity (ICO) in all definitions of MetS. The
group suggested that replacing waist circumference with ICO
Table 1. Criteria for clinical diagnosis of metabolic syndrome.
Clinical
Measure WHO(1998) EGIR (1999) ATP III (2001) AACE (2003) IDF (2005) AHA (2005)
Insulin
resistance
IGT, IFG, T2DM, or
lowered insulin
sensitivity plus any 2 of
the following
Plasma insulin
>75th percentile
plus any 2 of the
following
None, but any 3 of
the following 5
features
IGT or IFG plus any of
the following based
on clinical judgment
None None
Body weight Men: waist-to-hip ratio
>0.90; women: waist-to-
hip ratio >0.85 and/or
BMI >30 kg/m2
WC ≥94 cm in
men or ≥80 cm in
women
WC ≥102 cm in men
or ≥88 cm in
women
BMI ≥25 kg/m2 Increased WC (population
specific) plus any 2 of the
following
Waist circumference
≥ 102 cm in men
≥ 88 cm in women
Lipid TG ≥150 mg/dL and/or
HDL-C <35 mg/dL in men
or <39 mg/dL in women
TG ≥150 mg/dL
and/or HDL-C <39
mg/dL in men or
women
TG ≥150 mg/dL
HDL-C <40 mg/dL
in men or <50 mg/
dL in women
TG ≥150 mg/dL and
HDL-C <40 mg/dL in
men or <50 mg/dL in
women
TG ≥150 mg/dL or on TG Rx
HDL-C <40 mg/dL in men or
<50 mg/dL in women or on
HDL-C Rx
TG ≥150 mg/dL (1.7
mmol/L)
Or
On drug treatment for
elevated triglycerides
<40 mg/dL (1.03
mmol/L) in men
<50 mg/dL (1.3 mmol/
L) in women
Blood
pressure
≥140/90 mm Hg ≥140/90 mm Hg
or on
hypertension Rx
≥130/85 mm Hg ≥130/85 mm Hg ≥130 mm Hg systolic or ≥85
mm Hg diastolic or on
hypertension Rx
≥130 mm Hg systolic
blood pressure
or
≥85 mm Hg diastolic
blood pressure
or
on antihypertensive
drug treatment in a
patient with a history
of hypertension
Glucose IGT, IFG, or T2DM IGT or IFG (but
not diabetes)
>110 mg/dL
(includes diabetes)
IGT or IFG (but not
diabetes)
≥100 mg/dL (includes
diabetes)
IFG≥100 mg/dL
or
On drug treatment for
elevated glucose
Other Microalbuminuria None None Other features of
insulin resistance
Other None
T2DM, type 2 diabetes mellitus; WC, waist circumference; BMI, body mass index; TG, triglycerides; IGT, impaired glucose intolerance; IFG, impaired fasting glucose;
HDL-C, High Density Lipoprotein-Cholesterol. Modified from [15].
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in definitions of MetS might make it uniformly applicable
across genders and races. It also has the advantage of identify-
ing additional subjects who qualify to have MetS by the NCEP
ATP III definition but are missed by IDF global consensus
definition (16).
Effects of metabolic syndrome on the brain
MetS, as previously stated, is a multifactorial disorder repre-
sented by the co-occurrence of several vascular conditions
related to central obesity that also includes impaired glucose
metabolism, dyslipidemia, high BP and that depicts a risk
status for both T2DM and coronary artery disease (CAD).
Traditionally, vascular risk factors taken separately, such as
hypertension, dyslipidemia, and diabetes, have been shown to
play an important role in the development of Mild Cognitive
Impairment (MCI), dementia, and Alzheimer’s Disease
(AD) (17).
Most of the components of MetS have also been shown to
be independent risk factors for CAD and stroke. On the
other hand, MetS was already shown to be an independent
risk factor for CAD, and fatal and nonfatal stroke (18–21).
MetS appeared to increase the risk for age-related cognitive
decline (ARCD) (22–27), while for some authors, the find-
ings for MCI and its progression to dementia were too
limited to draw any conclusions (21,28,29). In fact, a study
found an association between MetS and the number of its
components and the risk of developing cognitive impairment
in older women with osteoporosis from clinical centers (28).
In a large longitudinal Italian population-based sample with
a 3.5-year follow-up, in a total of 2,097 participants from a
sample of 5,632 65- to –84-year-old subjects from the Italian
Longitudinal Study on Aging, among MCI patients, those with
MetS had a higher risk of progression to dementia compared
with those without MetS (22). Furthermore, several studies
suggested that MetS may be linked to the risk of developing
dementia and Vascular Dementia (VaD) (21,30–32). Several
individual components of MetS have been linked to risk of
developing dementia and cognitive impairment. Among the
five MetS components, hyperglycemia, lower HDL levels, and
elevated triglyceride levels were the components with increased
risk for predementia syndromes and for VaD (17,21,32)
In research conducted between 2009 and 2010, the authors
found that being afflicted by MetS is associated with a high risk
of developing mild cognitive impairment (amnestic type).
Among MetS components, central obesity showed a significant
association with amnestic mild cognitive impairment (aMCI)
(OR = 1.77; 95% CI 1.11–2.82). The association between MetS
and aMCI remained significant on repeated analysis among
subjects free of heart disease and stroke (33).
Another research published in 2011, by the authors of The
Italian Longitudinal Study on Aging, also reiterated that
among MCI patients the presence of MetS independently
predicted an increased risk of progression to dementia over
3.5 years of follow-up (21).
In contrast, some studies indicate that MetS could be
protective in some aged populations. In spite of what has
been said up to now, research conducted among men aged
75 and over in Taiwan showed that age and central obesity
were significant risk factors in cognitive decline, but late-life
MetS, however defined, had a protective effect on cognitive
function. The last conclusion of these papers was that further
investigation is needed to clarify the possible mechanism of
MetS and cognitive function in older adults (34).
Recently, a systematic review and meta-analysis, includ-
ing 19,522 subjects aged 59–85 years from 13 longitudinal
population-based studies, has been conducted to examine
the association between MetS and longitudinal changes in
cognitive functions. A small association was found in the
younger old group (≤ 70), but not in the older group (>70
years). The conclusion was that age appears to modify the
association between MetS and cognitive decline, and that
these results emphasize the importance of age-stratified risk
prediction models of dementia in subjects with chronic
metabolic disorders (6,7).
Epidemiology
A total of 56 million deaths occurred worldwide during 2012.
Of these, 38 million were due to noncommunicable diseases
(NCDs), principally cardiovascular diseases, cancer, and
chronic respiratory diseases (35). The number of NCD deaths
has increased worldwide and in every region since 2000, when
31 million lives were lost to NCDs. While the annual number
of deaths due to infectious diseases is expected to decline, the
total annual number of NCDs deaths is expected to increase
to 52 million by 2030 (36,37).
An estimated 17.5 million people died from CVD in 2012,
representing 31% of all global deaths. Of these deaths, an
estimated 7.4 million were due to coronary heart disease and
6.7 million were due to stroke. Over three-quarters of CVD
deaths take place in low- and middle-income countries.
The causes of heart attacks and strokes are usually the pre-
sence of a combination of risk factors, such as tobacco use,
unhealthy diet and obesity, physical inactivity and harmful use
of alcohol, hypertension, diabetes, and hyperlipidemia (38).
In Italy, standardized death rates from pathologies corre-
lated to MetS, such as T2DM, ischemic hearth diseases and
cardiovascular disease, have been declining, while the mortality
trend for AD and dementia is increasing (Tables 2).
Overweight and obesity were estimated to account for 3.4
million deaths per year and 93.6 million Disability-Adjusted
Life Years (DALYs) in 2010 (35). Obesity has been increasing
in all countries. In 2014, 39% of adults aged 18 years and older
(38% of men and 40% of women) were overweight. The world-
wide prevalence of obesity nearly doubled between 1980 and
2014. In 2014, 11% of men and 15% of women worldwide were
obese. Thus, more than half a billion adults worldwide are
classed as obese (39).
In the European and Eastern Mediterranean Regions and
Region of the Americas, over 50% of women are overweight,
and in all three regions roughly half of overweight women are
obese (25% in the European region, 24% in the Eastern
Mediterranean Region, 30% in the Region of the Americas). In
all WHO regions, women are more likely to be obese than men.
In the African, Southeast Asia, and Eastern Mediterranean
regions, women have roughly double the obesity prevalence of
men (40).
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In Italy, the Heart Project (Progetto Cuore) – Epidemiology
and Prevention of Ischaemic Heart Diseases – coordinated by
Istituto Superiore di Sanità (Italian Institute of Health), conducted
two researches on the health status of the Italian population
between 1998–2002 and 2008–2012 (9).
From these researches, some data have been emphasized:
– General population (35–74 years): the comparison
between the two surveys (1998–2002 and 2008–2012)
shows that LDL cholesterol levels rise in both men
(from 128 to 133 mg/dl) and women (from 126 to 134
mg/dl). The prevalence of hypertrigliceridemia is
unchanged in both genders (about 25%). MetS has
reduced both in men (from 29.2% to 23.5%) and in
women (from 29.6% to 18.5%). This trend was observed
in all regions of Italy (north, center, south, and islands).
– Older people (75–79 years): total cholesterol is higher in
women (217 mg/dl) than in men (193 mg/dl). The same
trend was observed for HDL cholesterol (61 mg/dl women
vs 51 mg/dl men) and LDL cholesterol (131 mg/dl women
vs 118 mg/dl men). Hypercholesterolemia is higher in
women than in men (54.8%, and 36.3%, respectively).
High levels of LDL cholesterol were observed in 65% of
women and in 51% of men. The prevalence of MetS in the
period 2008–2012 was high and similar in both genders
(35.9% in men, and 40.7% in women). It was observed that
the prevalence of MetS is higher in the older population
than in the general population.
The last data for Italy, published by WHO, refer to the
period between 2012 and 2014. These data indicate an
increase of body mass index (BMI) (from 25.9 to 26.0), of
the overweight (from 57.2% to 58.8%), and also of obesity
(from 19.6% to 21.0%) (41).
Diabetes is a well-recognized cause of premature death and
disability, increasing the risk of cardiovascular disease, kidney
failure, blindness, and lower-limb amputation (42). People
with impaired glucose tolerance and impaired fasting glyce-
mia are also at risk of future development of diabetes and
cardiovascular disease (43)
Prediabetes, which is a combination of excess body fat and
insulin resistance, is considered an underlying etiology of MetS.
Prediabetes manifests as impaired fasting glucose and/or
impaired glucose tolerance. Impaired fasting glucose is defined
as a fasting blood glucose level of 100 to 125 mg/dL; impaired
glucose tolerance requires a blood glucose level of 140 to 199
mg/dL 2 hours after a 75-g oral intake of glucose (44).
The prevalence of diabetes was estimated to be 9% in 2014,
and was highest in the WHO Region of the Eastern
Mediterranean Region (14% for both sexes) and lowest in
the European and Western Pacific Regions (8% and 9% for
both sexes, respectively). In Italy, data from WHO estimate
the increase on the prevalence of diabetes in the period
between 2012 and 2014 (from 6.3% to 6.6%) (41).
Social considerations
MetS has been found to be a risk factor for dementia, mild
cognitive impairment, and its associated states. As previously
introduced, a total of 56 million deaths occurred worldwide
during 2012. Of these, 38 million were due to NCDs, princi-
pally cardiovascular diseases, cancer, and chronic respiratory
diseases (36), although some data show a substantial decline
in age-adjusted prevalence of fatal and nonfatal myocardial
infarction in developed countries (45).
In Italy, disease-related cognitive dysfunctions show an
increasing trend due to the increase of some deadly diseases.
Italian people need to be protected against diseases of social
interest whose incidence is directly related to social and eco-
nomic factors (i.e., tumors, CVDs, AD, VaD, and T2DM).
The protection can take the form of social insurance and also
health insurance for national workers.
The latest recognition of MetS as an independent noso-
graphic condition has not yet led to sufficient processing of
theoretical practice of exclusive medicolegal interest.
Some authors (46) affirm that is possible to include the
syndrome in the disability list according to the Italian current
law (47) with a score in the range 11–20% disability.
The debilitating effects of MetS cannot be assessed simply
by adding up its associated pathologies, as this does not give
satisfactory answers to legal and medico-social issues.
Conversely, it will be necessary to increase assessment scores
to make sure that the final disability score is greater than the
sum of the single pathologies that make it up.
The development of thought of Forensic Medicine has
considered functional impairment as the basis for definition
of damage to specific personal skills in relationship to life
(social, family, work). In this way is possible to seize the
difficulties that MetS can cause: sociocultural disabilities
more than invalidity.
This is a dynamic abstract concept influenced by the parti-
cular historical-social period to which it refers. Moreover,
Italian Legislative Decree no. 509/88 (48) institutionalized
the disability evaluation table. It was only elaborated in
Table 2. Deaths per 100,000 population in Italy (standardised rates).
2000 2012
Circulatory system diseases 373.6 255.0
– Ischaemic Hearth Diseases 113.5 84.1
– Acute miocardial infarction 53.0 32.2
– Cerebrovascular diseases 105.1 67.2
Diabetes mellitus 27.1 24.3
Dementia 12.0 16.7
Alzheimer’s Disease 9.6 (*) 11.8
(*) Italian data on Alzheimer start from 2003. Modified from The Organisation for Economic Co-operation and Development (OECD) [77].
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1992, and it is still in use today despite its apparent failure.
That table was based on the International Classification of
Diseases formulated by the WHO in 1980, namely, the
International Classification of Impairments, Disabilities and
Handicaps (ICIDH) (49), and overcame the simple list of
pathologies. To consider the real impact of MetS, it became
necessary to examine interactions between human activities
and their social environment.
The WHO classification highlighted and redefined these
old concepts. In the new classification, only the term
“Impairment” has been preserved; Disability has been
replaced by Activity (all that a person is able to do at various
levels of complexity). To the inadequate notion of
“Handicap,” “Participation” was preferred, where the degree
of this depends on the relationship between the disabled
subject with compromised activity and environment. In May
2001, the audit trail of the WHO was concluded with the
development of the International Classification of
Functioning, Disability and Health (ICF) (50), subsequently
supplemented and improved with annual updates.
Without doubt, disability is defined as a consequence or
result of the relationship between the health condition of an
individual and personal and environmental factors.
During working life it is often difficult to reduce stress
levels, improve diet, and find time for physical activity. All
these deficiencies favor the development of MetS; and this
pathology increases the risk of serious diseases, which, first of
all, affect health, but also social costs and productivity (51,52).
Recently, in Italy, private insurance has introduced pro-
ducts dedicated to the evaluation of MetS, with a diagnosis
designed at controlling risk factors and preventing more ser-
ious clinical manifestations.
Insurance guarantees are justified by the real possibility of
an early diagnosis, obtained by simple medical investigation
and affordable screening. Furthermore, both the insured and
the insurer have the advantage of controlling possible greater
economic damage resulting from a late diagnosis, with the
clinical risk of related diseases involving more demanding and
costly care already established.
MetS is not only a medical-legal problem but also a med-
ical-social dilemma. It is not possible to include MetS in a
simple evaluation that is linked to only a reduced work
capacity. It is necessary to review the concept of disability
and talk of the social concerns associated with MetS. Action
should be taken regarding the causes of the disease to decrease
the level of disability defined as limitation of the activities of a
subject with MetS.
In conclusion, the medicolegal aspects must be identified
and the research and prevention of causes of MetS must
increase. A joint action is required to contain the incidence of
MetS, its high social costs, and correlated loss of productivity.
Costs of metabolic syndrome
It is not easy to evaluate the costs of MetS, while costs for each
pathology (that contribute to identify MetS) are more easy to
calculate, such as for medicolegal evaluations of this
pathology.
To analyze social costs, it is necessary to consider three
categories of costs: direct, indirect, and intangible (53,54).
Direct costs derive from medical and non-medical care (e.g.,
prevention, diagnosis, and therapy). Indirect costs represent
lack of wealth production due to the illness and the time
relatives and caregivers devote to health care. Intangible
costs are linked to pain, anxiety, physical, and psychological
suffering of the patient and its relatives. These costs are
difficult to evaluate, but are considerable in terms of their
social and human aspects (55).
The direct cost burden of a person with diabetes varies
considerably across countries. For example, in Italy in 2010,
the costs for each patient were on average € 2,756,00 (of which
€814 for drugs, €373 for check-ups and medical care, €1,569
for hospitalization). In the EU, France, Germany, and the UK
have considerably higher costs per diabetes patient (€5,432;
€5,899; €4,744, respectively) than in Spain (€1,708). Many
diabetic patients experience multiple complications, com-
pounding the complexity of treatment and thus costs (56).
In Italy, total expenditure on medicines in 2010 amounted
to €2.34 billion (31.8% of total direct cost), of which €492
milion for antidiabetic drugs (6.2% of total direct cost) and
the remainder for drugs treating comorbidities and complica-
tion of diabetes (56).
Regarding indirect costs, every year, diabetic people work-
ing in Italy (1.33 million) are absent from work for 33 days
because of illness, with productivity costs of € 8 billion. The
total indirect costs in Italy are evaluated as being €17 bil-
lion (56).
The same study highlighted that in the countries consid-
ered (Italy, France, UK, Germany, Spain), costs due to dia-
betes are about €200 billion per year (56).
Some authors developed a probabilistic prevalence Cost-of-
Illness model in order to calculate an aggregate measure of the
economic burden associated with diabetes, in terms of direct
medical costs (drugs, hospitalizations, monitoring, and
adverse events) and indirect costs (absenteeism and early
retirement). The model estimated a predominance of 2.6
million patients undergoing drug therapy in Italy. The total
economic burden of diabetic patients in Italy amounted to
€20.3 billion per year (95% CI, from €18.61 to €22.29 billion),
54% of which are associated with indirect costs (95% CI,
€10.10 to €11.62 billion) and 46% with direct costs only
(95% CI, €8.11 to €11.06 billion) (57).
High blood pressure has long been recognized as a major
health burden and particularly as a major risk factor for
overall mortality affecting all segments of the population.
During the first 25 years of the 21st century, the disease
burden of hypertension is expected to increase by 60% glob-
ally, with an estimated 1.56 billion hypertensive individuals in
the world. As morbidity and mortality shift from communic-
able diseases, high blood pressure will significantly increase in
economically developing countries so as to represent nearly
half of the disease burden due to increased hypertension-
related outcomes (58).
In Italy, healthcare costs for hypertension amounted to
€2783.2 million in 2011. Added to expenditure for lipid-low-
ering drugs, these costs amount to €4156.7 million (59).
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In 2012, expenditure for cardiovascular drugs remains
highest in Italy, with a figure of €4.350 million. Compared
to other European countries, Italy has the highest public and
private spending for cardiovascular drugs (24.7%), after
Portugal (27.9%) and Greece (31.5%) (59).
Obesity is responsible for both high direct costs (due to
treatment for associated illnesses such as diabetes, hyperten-
sion, and cardiovascular diseases) and indirect costs, for the
decrease in workforce productivity due to illness and early
deaths. In US adults, a study examined the impact of obesity
on healthcare expenditures (payments for office and hospital-
based care, home healthcare, dental services, vision aids, pre-
scription medicines). It was found that, when compared to
normal-weight adults, per capita healthcare expenditures were
nearly 10% greater for the overweight, and about 23%, 45%,
and 81% greater for persons with class I, II, III obesity,
respectively (60). Studies from the USA suggest that the
impact of obesity on annual medical spending is especially
pronounced for prescription drugs, while European studies
found that direct costs differ according to patient character-
istics, for example, by health-status, socio-demographic, and
economic aspects (61–63).
In Italy, the SiSSI project estimated that being overweight is
responsible for 4% of costs (€4.5 billion in 2012). The same study
reported that spending on healthcare is 3% higher in overweight
people (BMI 25–29.9), 18% higher in obese people (BMI
30–34.9), 41% higher in severely obese people (BMI 35–39.9),
and 50% higher in very severely obese people (BMI ≥ 40). In the
author’s opinion, a severe/very severe obese person costs
450–550 €/year more than a normal-weight person (64).
As previously shown, MetS is directly related to the devel-
opment of CVD. Consequently, MetS could contribute to an
increase in the frequency and costs of such diseases. In fact,
based on estimates from the World Alzheimer Report 2010,
the number of people with dementia has increased by 31.5%
between 2010 (35.6 million) and 2015 (46.8 million). Between
2010 and 2015, the average worldwide cost per person (a
weighted average across countries, calculated on a ‘like for
like’ basis) increased from US$15,122 to US$17,483 US$ per
year (an increase of 15.6% or 3.1% per year).
The global costs of dementia increased from US$ 604
billion in 2010 to US$ 818 billion in 2015, an augmentation
of 35.4%. The proportion of worldwide costs incurred in
upper-middle-income countries (UMICs) has increased from
5.4% to 10.5%. In 2015, the mean cost per person with
dementia was US$ 43,680 in G7 countries, US$ 20,187 in
G20 countries, and US$ 6,757 in countries that were members
of neither G7 nor G20 (65). Total European 2010 cost of brain
disorders was €798 billion, of which direct healthcare cost
37%, direct nonmedical cost 23%, and indirect cost 40%.
The average cost per inhabitant was €5.550. The European
average cost per person with a brain disorder ranged from
€285 for headaches and €30,000 for neuromuscular disorders.
In particular, the total annual cost of dementia (in billions of
euros, 2010) was €105.2 (66).
Forecasts based on population projections in Europe seem to
indicate an increase of about 43% of these costs by 2030 (67).
In Italy, each Alzheimer’s patient costs about €60,000 per
year. An amount that takes into account both direct costs for
the purchase of services and benefits and indirect costs (care
and supervision monetized hours). The first, amounting to
€15,000, accounts for 25% of the total and are mainly sup-
ported by families (68).
Conclusion
Due to the importance of MetS and its relations with the CVD
and AD, prevention is the most important strategy to fight the
disease and its outcomes. Several authors agree on the impor-
tance of changes in lifestyle. In patients with prediabetes, the
rate of progression to diabetes within 3 years can be decreased
by approximately 58% with lifestyle modifications. These
include weight loss through physical exercise (30 minutes or
more of moderate physical activity on most, preferably all,
days of the week) and dietary modifications as also recom-
mended by IDF.
In fact, the primary strategy for MetS management, to
reduce the risk of developing cardiovascular and cerebrovas-
cular disease, is consuming an overall healthy diet for weight
reduction and continuous weight maintenance (69–76).
Healthy diets are recommended, particularly the
Mediterranean diet (69).
For these reasons, it is important to focus on information
and screening campaigns targeting most-at-risk populations
(e.g., overweight or with a family history of diabetes),
encouraging exercise in daily activity and including medical
experts such as dieticians and psychologists, thus helping
people achieve a good glycemic control and more generally
an acceptable level of health
The best approach seems to be a combination of health
strategies, aimed at individuals who are more at risk of obesity
(children, middle-to-lower class income groups, and minority
groups). In the studies taken into consideration, the cost of a
package of health initiatives varies from $12 pp in Japan to
$24 pp in Canada and the USA. In all these countries, where
coverage and services are different, this cost unfortunately
represents an extremely low percentage of total healthcare
expenditure, including costs related to prevention.
According to OSCE, the highest costs are incurred by
primary care, while tax measures are understandably the
most cost-effective. In particular, Sassi (77) underlines the
importance of directing various health initiatives to children,
in other words to age-groups which are potentially prone to
obesity. In this case, results can only be appreciated in the
long term, but are more sustainable: community-based
results, acting as a social-multiplier, exceed individually-
based outcomes. The State, as a consequence, can and should
intervene to avoid the increase of overweight and obesity rates
(according to data from the PASSI study, in some regions of
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the south, overweight and obesity rates in children under 15
years of age are equal to 50%) (78).
In the field of prevention, the European Union has sup-
ported its member states in their efforts. These initiatives can
aid in the definition of shared objectives and indicators, sharing
best practice, and ensuring regular observation and evaluation.
As has already been done for other pathologies, an
International Study Group for MetS could be established. In
view of cross-border healthcare, this would allow joint health-
care initiatives to be adopted, reducing healthcare costs as well
as aiding in the prevention and promotion of good health.
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